CELL AND GENE THERAPY, INDUSTRIAL IMPACT
GenScript | March 03, 2023
GenScript Biotech Corporation, a leading tools and services provider for life-science research, recently announced the expansion of its Singapore facility to provide a high-quality gene synthesis service. This expansion has added 976 square meters to the facility, bringing its total size to 3,500 square meters, making it the third-largest facility for GenScript globally. This development will also increase the staff at the Singapore facility to 150.
In February 2022, GenScript Asia-Pacific opened a recombinant protein production facility, which will now offer an advanced gene synthesis service. This expansion is a significant step towards GenScript's aim to provide top-notch services required for novel vaccine and therapeutic development in the life-sciences field.
The Singapore facility uses modernized, automated workstations that can synthesize more than 400 genes daily, ensuring precise measurement, eliminating human error, and providing a consistently high-quality product. The new facility's goal is to decrease project turnaround time for a more global mix of clients while maintaining customer data security. The new facility's capacity is dedicated to gene and cell therapy research and vaccine development programs.
GenScript's Life Science Group President, Dr. Ray Chen, commented, "We understand that global supply is a huge challenge, and we remain committed to expanding our reach to meet the increasing demand for our customers worldwide. At GenScript, we take great pride in our ability to provide reliable and efficient solutions to our customers, and we are fully committed to delivering on this promise. As we continue to expand our global footprint, we remain dedicated to providing the highest-quality products and services to our customers, wherever they may be located."
(Source – PR Newswire)
Founded in 2002, GenScript is a leading biotech firm. It has a global presence across the EU, North America, Greater China and Asia Pacific and has served more than 300,000 customers from over 160 countries and regions around the world. With more than 5,000 employees, it is dedicated to providing premier, convenient, and reliable products and services. The company strongly focuses on technology development, with over 100 patents and 270 patent applications in fields such as immunotherapy, synthetic biology, chemical synthesis, antibody design and bioinformatics. GenScript's products and services have been cited in 74,700 scientific papers worldwide as of June 2022. The company's vision is to become the most reliable biotech company in the world, working towards the betterment of human and environmental health through biotechnology.
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Bio-Techne Corporation | March 20, 2023
Bio-Techne Corporation announced it has completed its participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year collaboration involving 24 partner companies, technology providers, therapy developers, and charities. The Catapult PAT consortium is the first initiative of this scale and functional expertise with member companies and organizations collaborating to develop cell and gene therapy-specific process analytical technologies.
The PAT initiative began in January 2021 with a series of experiments designed to monitor process parameters of an exemplar 8-day T-cell expansion bioprocess using primary T-cells. Data were gathered from five independent analyses to generate an extensive, world-first dataset. An analysis of multiple cytokine targets was conducted using high-plex Luminex® immunoassays and the precision multiplexing Ella™ platform from Bio-Techne. The automated workflow of the Ella platform proved to be particularly amenable to the efficiency, accuracy, and throughput demands inherent in a bioprocess manufacturing environment. With its robust performance in this project, the Cell and Gene Therapy Catapult plans to incorporate Ella™ into an existing CGT Catapult facility to further support scientists in the UK.
"As a leader in the forefront of innovative tools to measure cytokines, we are honored to be a part of the Catapult PAT initiative to help advance cell and gene therapy development," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "Bio-Techne remains excited about the potential of these advanced therapies to improve patient outcomes and treat a wide range of diseases that currently have very poor or ineffective treatments."
Established by Innovate UK, the Cell and Gene Therapy Catapult fosters collaborations between academia, industry, and healthcare providers to develop new technology and drive innovation. Catapult experts cover all aspects of advanced therapies, from research and development to clinical adoption and every step in between.
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and has approximately 3,000employees worldwide.
INDUSTRIAL IMPACT, MEDICAL
Inscripta, Inc. | January 24, 2023
Inscripta®, a leading global life science technology firm, recently announced the acquisition of two synthetic biology pioneers, Infinome Biosciences and Sestina Bio, which will advance Inscripta's strategy of developing and commercializing biomanufactured products for a wide expanse of industrial and consumer markets.
The acquisitions show Inscripta's belief in the bioeconomy's commercial potential and the power of genome engineering to expedite biomanufacturing innovation. Inscripta's CEO, Sri Kosaraju, commented, "Tackling the unprecedented opportunity to improve global health and sustainability through biomanufacturing requires a strong combination of talent, experience, technology, and commercial assets." He added, "Infinome and Sestina Bio allow us to advance our strategy and complement our technological innovation and capabilities needed for creating the next generation of biobased manufacturing products and processes."
(Source- PR Newswire)
Before the acquisition, Infinome was closely associated with Inscripta. By utilizing Inscripta's genome engineering technology, it created the GenoScaler™, a proprietary strain engineering platform designed to optimize microorganisms for biomanufacturing rapidly.
Sestina Bio brings an innovative, data-driven approach to developing and identifying strains that survive the rigors of commercial scale-up.
Inscripta is building on its tradition of technological innovation with the inclusion of Infinome and Sestina Bio and has already begun applying its cutting-edge technology to develop products for a diverse set of industrial and consumer markets. In addition, Inscripta has a number of collaborative and proprietary products in various phases of development. One such example of an announced partnership to develop and commercialize multiple bio-manufactured goods is Kalsec® Inc., a food and beverage ingredient solutions firm. Separately, Inscripta is engaging in commercial discussions about its previously announced development of a ready-to-scale microbial strain that produces Bakuchiol, a natural retinol alternative.
About Inscripta, Inc.
Founded in 2015, Inscripta is a life science technology firm dedicated to using biomanufacturing to create a cleaner, healthier, and more sustainable world. It enables scientists to strengthen and expand domestic biomanufacturing and encourages the development of novel, safe, and secure biotechnology technologies. Its automated OnyxTM platform, which includes an instrument, consumables, tests, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports customers globally through its facilities in Boulder (Colorado), San Diego and Pleasanton (California) and Copenhagen (Denmark)